Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statins versus PCSK9 inhibitors for bone metabolism in women with type 2 diabetes
ChiCTR2600130942Phase 4Not yet recruiting
- Sponsor
- Yangpu District Central Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atorvastatin in osteoporosis, hyperlipidemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yangpu District Central Hospital. Primary endpoints: Lumbar bone density, Total hip bone density and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
osteoporosishyperlipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600130942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130942.